DUR-928 is also being investigated in patients with nonalcoholic steatohepatitis (NASH). 89% of the overall DUR-928 patient population were treatment responders based on Lille. We may report additional efficacy signals of this trial at a future medical conference. Indivior commercially launched PERSERIS in the U.S. in February 2019. Diversify Risk by Pursuing Multiple Programs in Development. This license includes rights to nine patent families. There can be no assurance that the pending patent applications will be granted. In the United States, POSIMIR is covered by four patent families. These efforts by us may not be successful. Our submission of an IND may not result in FDA authorization to commence clinical trials. These entities represent significant competition for us. Our Code of Ethics can be found on our website. Norman L. Sussman, M.D., FAASLD, joined DURECT as Chief Medical Officer in November 2020. We are currently developing DUR-928 in several indications, including AH and NASH. We cannot predict how successful we will be at enrolling patients in our clinical trials. Indivior has stated that it launched PERSERIS in February 2019 in the United States. Any of our present or future collaborators may not perform their obligations as expected. It also initiated the imposition of tariffs on certain foreign products.